2[2]Mytilineou C,Kramer BC,Yabut JA.Glutathione depletion and oxidative stress[J].Parkinsonism Relat Disord,2002,8(6):385-387.
3[3]Kedar NP.Can we prevent Parkinson's and Alzheimer's disease[J] J Postgrad Med,2003,49(3):236-245.
4[4]Jenner P.Altered mitochondrial function.iron metalolim and glutathione levels in Parkinson's disease[J].Acta neruol Scand,1993;87(Suppl):146
5[5]Paik SR,Lee D,Cho HJ,et al.Oxidized glutathione stimulated the amyloid formation of alpha synuclein[J].FEBS Lett,2003,537 (1-3):63 -67.
6[6]Martignoni E,Blandini F,Godi L,et al.Peripheral markers of oxidative stress in Parkinson's disease.Therole of L-DOPA[J].Free Radic Biol Med,1999,27 (3-4):428-437.
7[7]Offen D,Iziv H.sternin et al.Prevention of Dopamine inuced cell Death by Thiod anvioxidants:Possible implications for treatment of Parkinosn's deasese experimental[J],Neurology,1996,141:32～39
8[8]Sechi G,Deledda MG,Bua G,et al.Reduced intravenous glutathione in the treatment of early Parkinson's disease[J].Prog Neuro psychopharmacol Biol Psychiatry,1996,20(7):1159-1170.
9Giladi N, TrevesTA, Simon ES, et al. Freezing of gait in patients with advanced Parkinson's disease[J]. J Neural Transm, 2001,108:53.
10Lingor P, Unsicker K, Krieglstein K. GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide[J]. Exp Neurol, 2000,63: 55.
4Ferreia JJ, Thalamas C, Montastruc JL, et al. Levodopa montherapy can indue "sleep attacks" in Parkinson's disease patients[J]. J Neurol, 2001,248(5) :426.
5Monlina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinaon's disease: a behavioral manifestation of pharmacologic treatment [ J ] ?. Mov Disord , 2000,15 (5) : 869.
6Evidente VG, Adler CH, Caviness JN, et al. A pilot study on the mother effects of rimantadine in parkinson' s disease [ J ]. Clin Neurophamacol, 1999,22 ( 1 ) : 30.
